Comparative oncology approach to drug repurposing in osteosarcoma.

about

Comparative oncology approach to drug repurposing in osteosarcoma.

Item

http://www.wikidata.org/entity/Q52631134

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Comparative oncology approach to drug repurposing in osteosarcoma.

@en

Comparative oncology approach to drug repurposing in osteosarcoma.

@nl

type

Item

label

Comparative oncology approach to drug repurposing in osteosarcoma.

@en

Comparative oncology approach to drug repurposing in osteosarcoma.

@nl

prefLabel

Comparative oncology approach to drug repurposing in osteosarcoma.

@en

Comparative oncology approach to drug repurposing in osteosarcoma.

@nl

P1476

Comparative oncology approach to drug repurposing in osteosarcoma.

@en

P2093

Alejandro Parrales

http://www.w3.org/2001/XMLSchema#string

Frank J Shoenen

http://www.w3.org/2001/XMLSchema#string

Kathleen A Neville

http://www.w3.org/2001/XMLSchema#string

Megan Ottomeyer

http://www.w3.org/2001/XMLSchema#string

Melinda Broward

http://www.w3.org/2001/XMLSchema#string

Peter McDonald

http://www.w3.org/2001/XMLSchema#string

Scott J Weir

http://www.w3.org/2001/XMLSchema#string

Tomoo Iwakuma

http://www.w3.org/2001/XMLSchema#string

Tyce Bruns

http://www.w3.org/2001/XMLSchema#string

P2860

Drug development: Raise standards for preclinical cancer research

Thioredoxin reductase

A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target

What do we know about canine osteosarcoma treatment? Review

ROS homeostasis and metabolism: a dangerous liason in cancer cells

Auranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53

Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes).

Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program

Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.

Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.

P304

e0194224

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0194224

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Douglas H Thamm

Anuradha Roy

Joy M Fulbright

P577

2018-03-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29579058

http://www.w3.org/2001/XMLSchema#string

P932

5868798

http://www.w3.org/2001/XMLSchema#string